A novel Bayesian decision procedure for early-phase dose-finding studies.

Abstract

Phase I first-in-man studies in normal, healthy volunteers are performed to define a maximum safe dose and to identify a range of acceptable doses for later drug development studies in patients. Analysis of pharmacokinetic and pharmacodynamic data using mixed-effects modeling can be used to fit an overall dose-response relationship. By expressing prior information as pseudodata, the same methodology can be used to perform a Bayesian analysis and to determine posterior modal estimates for the model parameters. Decision theory can then be applied to maximize a chosen gain function, utilizing real-time data capture for choosing safe doses in a way that will provide more informative responses, thus accelerating study completion. The methodology is introduced elsewhere (1). The purpose of this paper is to describe software currently in development and to illustrate the method using an example from a recent study.

05010015020072008200920102011201220132014201520162017
Citations per Year

161 Citations

Semantic Scholar estimates that this publication has 161 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Patterson1999ANB, title={A novel Bayesian decision procedure for early-phase dose-finding studies.}, author={S Patterson and Soosan Francis and M J Ireson and David Webber and John Whitehead}, journal={Journal of biopharmaceutical statistics}, year={1999}, volume={9 4}, pages={583-97} }